CD19 antibody from Biorbyt

Application Notes: FMC63 was used for four years as a CD19 antibody in various labs prior to its original publication. There, it was reported that the antibody percipitates CD19 and inhibits the binding of other CD19 antibodies to it (Zola et al., 1991; PMID: 1725979). FMC63 was used for IF and FACS of peripheral blood mononuclear cells (PBMC) from patients with multiple myeloma (MM) (Szczepek et al., 1997; PMID: 9057669) and receptor for hyaluronan (HA)-mediated motility (RHAMM) expressing malignant B-lineage cells in myeloma (Crainie et al., 1999; PMID: 10029598). FMC63 was used for IHC and IIP of B cells in lymphocyte-filled villi and IIP of jejunal isolated lymphoid follicle, respectively, in small bowel specimens from human patients (Moghaddami et al., 1998; PMID: 9834269). FNC63 was used to induce B cell depletion in vivo (DiLillo et al., 2011; PMID: 21248259). FMC63 has been incorporated into a CD19 scFv- 41BB- CD3ζ fusion protein-encoding lentiviral vector, which was used in combination with a UCART19 cell therapy to cure high-risk CD19+ infant acute lymphoblastic leukemia (Qasim et al., 2017). This clone did not compete with clone HD37 (available as Ab00214) (Sakemura et al., 2023; PMID: 37879074).